Twenty-four percent mean body weight reduction in a Phase 2 trial. That number has been circulating everywhere in obesity research, and it earns the attention. It's bigger than anything previously published for a drug in this class. It's also, right now, close to the entire sum of what we reliably know about retatrutide in actual humans.
What you're actually looking at
Retatrutide is Eli Lilly's next step past tirzepatide. Tirzepatide works by activating two gut hormone receptors, GIP and GLP-1. Retatrutide activates three, adding glucagon into the mix. That third receptor is the new piece nobody else has.
You probably think of glucagon as the emergency hormone that raises blood sugar. It does that, but it also drives energy expenditure and pushes your liver to burn fat. Adding glucagon receptor activation on top of GIP and GLP-1 is what researchers think explains why retatrutide's numbers beat tirzepatide's. The glucagon piece appears to add an energy-burning effect the other two pathways don't fully reach on their own.
Retatrutide isn't FDA-approved. As of 2026, it's still in Phase 3 trials, and it isn't available through any pharmaceutical channel.
The part that actually matters if you're a woman watching this
Everyone's fixated on the weight loss number, but the liver finding is the one I'd point you to.
Metabolic dysfunction-associated steatotic liver disease, fatty liver disease driven by metabolic changes rather than alcohol, is chronically underdiagnosed in women and tends to get worse through and after perimenopause as estrogen drops and metabolism shifts under you. A parallel Phase 2 analysis published in Nature Medicine found retatrutide substantially reduced liver fat, with a meaningful share of participants seeing their steatosis resolve entirely by 48 weeks. The glucagon piece is thought to work through direct fat-burning effects in the liver itself. If you're navigating midlife metabolic shifts, that's a signal worth actually watching, not just the headline weight number.
What the research actually shows
One Phase 2 trial. 338 adults with obesity, 48 weeks, published in the New England Journal of Medicine in 2023. At the highest dose, 12 mg weekly, mean weight reduction landed around 24.2%, against 2.1% for placebo. The effect was clearly dose-dependent, more drug meant more weight loss, up through 12 mg. The trial also tracked improvements in blood pressure, triglycerides, waist circumference, and blood sugar markers.
The separate Nature Medicine liver analysis confirmed the fat-reduction findings. A 2025 study in animal models found that retatrutide reduced obesity-driven tumor growth, an early research direction, not a clinical finding in people, but one more data point on what glucagon receptor activation might do beyond weight.
What we honestly don't know yet
Phase 3 trials are still running as of 2026. No results published yet. That means no long-term safety data exists, no cardiovascular outcomes data, no established dosing protocol for approved use, and no real information about what happens to your weight once treatment stops. The tirzepatide data suggests regain is likely, but that's an inference borrowed from a different compound, not evidence specific to retatrutide.
The glucagon receptor piece, the exact feature that sets retatrutide apart from everything before it, also raises monitoring questions that GLP-1-only compounds simply don't have. Glucagon raises blood glucose and heart rate. Nobody actually knows yet how sustained triple receptor activation plays out in a human body over years. Researchers on the compound have flagged this as something the Phase 3 program needs to watch closely.
That 24% weight loss figure comes from 338 people over 48 weeks. That's a strong Phase 2 result. It is not a Phase 3 result. The sample size, duration, and patient selection in that trial weren't built to catch cardiovascular outcomes, long-term weight maintenance, or safety signals that only show up with more time and more people. Phase 3 data is what will actually settle this.
Research peptide vendors sell retatrutide as a research compound, and that product is not the pharmaceutical compound used in the trials above. It isn't made to the same manufacturing standards, and purity and concentration accuracy vary meaningfully by source.